Gsa Capital Partners LLP Arbutus Biopharma Corp Transaction History

Gsa Capital Partners LLP

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$2.24 - $3.06 $2,770 - $3,785	-1,237 Reduced 3.24%	36,923 $84,000
Q1 2023 May 12, 2023	SELL	$2.23 - $3.1 $176,239 - $244,996	-79,031 Reduced 67.44%	38,160 $115,000
Q4 2022 Feb 13, 2023	BUY	$1.91 - $2.85 $42,766 - $63,814	22,391 Added 23.62%	117,191 $273,000
Q3 2022 Nov 14, 2022	BUY	$1.88 - $2.88 $147,888 - $226,552	78,664 Added 487.51%	94,800 $181,000
Q2 2022 Aug 09, 2022	SELL	$1.98 - $3.17 $32,307 - $51,724	-16,317 Reduced 50.28%	16,136 $44,000
Q1 2022 May 11, 2022	BUY	$2.42 - $3.98 $78,536 - $129,162	32,453 New	32,453 $97,000
Q2 2021 Aug 05, 2021	SELL	$2.5 - $3.51 $774,597 - $1.09 Million	-309,839 Closed	0 $0
Q1 2021 May 10, 2021	BUY	$3.14 - $4.84 $890,560 - $1.37 Million	283,618 Added 1081.64%	309,839 $1.03 Million
Q4 2020 Feb 03, 2021	BUY	$2.76 - $4.97 $72,369 - $130,318	26,221 New	26,221 $93,000

138

95.5M

3.44M

377K

Ticker ABUS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 149,951,008
Market Cap $577M
Description
Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical tria...

Get notified when there are updates to the investment portfolio of Gsa Capital Partners LLP, based on Form 13F filings with the SEC.

Stay updated on Gsa Capital Partners LLP with notifications on news.